title: Induction treatments for acute promyelocytic leukemia: a network meta-analysis.
abstract: BACKGROUND
  9 treatments for acute promyelocytic leukemia (APL) have been compared in many randomized controlled trials (RCT). The conclusions have been inconsistent and the purpose of this study is to conduct a network meta-analysis.
  
  
  RESULTS
  Rankings of event-free survival are ATRA+RIF (81.2%), ATRA+ATO (69.6%), ATO (50.6%). Rankings of complete remission are ATRA+RIF (79.3%), ATRA+ATO (64.8%), RIF (60.3%), ATO (55.9%). Rankings of avoiding differentiation syndromes are CT (84.3%), ATO (80.3%), RIF (71.6%), ATRA+RIF (49%), ATRA+ATO (40.8%).
  
  
  METHODS
  A total of 1,666 patients from 12 RCTs were enrolled. The frequentist method was used. Relative risks with 95% confidence intervals were calculated. We produced a network plot, a contribution plot, and a forest plot predictive intervals. The inconsistency factor, the surface under the cumulative ranking curve and the publication bias were evaluated.
  
  
  CONCLUSIONS
  ATRA+ATO is eligible to be the first-line treatment for APL. ATRA+RIF is a prospective alternative to the first-line treatment. RIF or ATO should be reconsidered as another option for de novo APL.
authors.affiliation: Shenzhen Bone Marrow Transplantation Public Service Platform, Department of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518000, China.
authors.forename: Junjie
authors.initials: J
authors.lastname: Huang
authors.affiliation: Department of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China.
authors.forename: Min
authors.initials: M
authors.lastname: Sun
authors.affiliation: The University of Sydney Medical School, Sydney, NSW 2006, Australia.
authors.forename: Zitong
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Shenzhen Bone Marrow Transplantation Public Service Platform, Department of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518000, China.
authors.forename: Qiaoxia
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: Shenzhen Bone Marrow Transplantation Public Service Platform, Department of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518000, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Lou
authors.affiliation: Shenzhen Bone Marrow Transplantation Public Service Platform, Department of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518000, China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Cai
authors.affiliation: Shenzhen Bone Marrow Transplantation Public Service Platform, Department of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518000, China.
authors.forename: Weihong
authors.initials: W
authors.lastname: Chen
authors.affiliation: Shenzhen Bone Marrow Transplantation Public Service Platform, Department of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518000, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Du
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy; D007223:Infant; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010087:Oxides / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D014212:Tretinoin / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D001152:Arsenicals; D010087:Oxides; D014212:Tretinoin; D000077237:Arsenic Trioxide
keywords: acute promyelocytic leukemia; induction treatment; network meta-analysis